The invention relates in one aspect to polypeptides, such as polypeptides comprising an immunoglobulin variable domain (IVD), binding to human Programmed Death Ligand-1 (huPDL1), wherein the amino acid sequence of the polypeptide is comprising a CDR1 region, a CDR2 region, and a CDR3 region, wherein the CDR1, CDR2 and CDR3 regions are selected from those CDR1, CDR2 and CDR3 regions, respectively, as present in any of SEQ ID Nos:1, 5, 8 or 11. Methods for delineating or determining CDR regions include the Kabat, Chothia, Martin, and IMTG methods. In particular, the huPDL1-binding polypeptides comprise CDR regions of any of SEQ ID Nos:1, 5, 8 or 11 as determined by the IMTG method wherein the CDR1 region is chosen from SEQ ID Nos: 2 and 6, the CDR2 region is chosen from SEQ ID Nos: 3, 7, or 9, and the CDR3 region is chosen from SEQ ID Nos:4, 10, or 12. Further more specifically, the CDR regions are the CDR regions as present in SEQ ID NO:5.
In the above, the CDR regions may be humanized and/or the IVD may be humanized.
Furthermore in the above, the huPDL1-binding polypeptides may further comprise a functional moiety such as a detectable moiety.
The invention also relates to isolated nucleic acids encoding an above huPDL1-binding polypeptides, to vectors comprising such nucleic acid. Further included are host cells expressing an above huPDL1-binding polypeptide, host cells comprising an above nucleic acid or comprising an above vector. Pharmaceutical compositions comprising any of the above huPDL1-binding polypeptides are likewise part of the invention.
The above huPDL1-binding polypeptides, or the above pharmaceutical composition, find applications such as for use as a medicament, for use in diagnosis, for use in surgery, for use in treatment, or for use in therapy monitoring, and, more specifically, for use as an imaging agent. The invention further relates to methods for producing an above huPDL1-binding polypeptide, such methods comprising the steps of:
- expressing the huPDL1-binding polypeptide in a host cell as described above; and
- purifying the expressed huPDL1-binding polypeptide.
In one embodiment, such methods may further comprise the coupling of a detectable moiety to the purified huPDL1-binding polypeptide.
Original languageEnglish
Publication statusIn preparation - 2018


Dive into the research topics of 'human PD-L1 binding immunoglobilins: EP 18159388.0. / JoVG/huPDL1/626'. Together they form a unique fingerprint.

Cite this